Race to the Finish Line
Abbott Going Toe to Toe with Gilead in Oral HCV Regimen
By Marie Powers
Monday, October 15, 2012
In recent months, Gilead Sciences Inc. appeared to be in the driver's seat in the race for an all-oral, interferon-free hepatitis C virus (HCV) regimen. However, Abbott's posting of the first Phase III trial of its combination HCV regimen on ClinicalTrials.gov puts Gilead on notice that it won't cross the finish line unchallenged.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.